Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB001

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 07, 2020

            Details:

            Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB0139

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            Galecto has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ensifentrine,Tiotropium Bromide

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            Subgroup analysis of Phase 2b data will be provided by Verona Pharma showing that nebulized ensifentrin as monotherapy or applied to tiotropium enhances lung function in moderate to serious COPD patients regardless of smoking status or chronic bronchitis history over 4 weeks.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Humanetics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 19, 2020

            Details:

            Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ensifentrine

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 19, 2020

            Details:

            Company has initiated second, multiple dose, part of a Phase 2 trial to evaluate the pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mosedipimod

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EC-18

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 14, 2020

            Details:

            The US-based Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EC-18 in preventing the progression of COVID-19 infection to severe pneumonia or ARDS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etokimab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANB020

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 08, 2020

            Details:

            AnaptysBio presented full data from its Phase 2a proof-of-concept clinical trial of etokimab in adult patients with severe eosinophilic asthma at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB001

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sargramostim

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Leukine

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement August 04, 2020

            Details:

            Funding will support two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Razuprotafib

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: MTEC

            Deal Size: $5.1 million Upfront Cash: Undisclosed

            Deal Type: Funding August 04, 2020

            Details:

            Aerpio is developing a selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and inflammation.

            PharmaCompass